Rankings
▼
Calendar
REGN Q2 2016 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
REGN
Regeneron Pharmaceuticals, Inc.
$80B
Q2 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1.2B
Gross Profit
$1.1B
94.3% margin
Operating Income
$292M
24.0% margin
Net Income
$196M
16.2% margin
EPS (Diluted)
$1.69
QoQ Revenue Growth
+1.0%
Cash Flow
Operating Cash Flow
$399M
Free Cash Flow
$261M
Stock-Based Comp.
$132M
Balance Sheet
Total Assets
$6.2B
Total Liabilities
$2.1B
Stockholders' Equity
$4.1B
Cash & Equivalents
$647M
Revenue Segments
Antibody Collaboration
$111M
68%
Immuno-oncology Agreement
$52M
32%
← FY 2016
All Quarters
Q3 2016 →
